Evidence map›Paper›PMID 36517075›Full record

ArticleInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society2023

Validation of a risk-based algorithm to reduce poor operative outcomes after complex surgery for ovarian cancer.

Deepa Maheswari Narasimhulu, Anna Fagotti, Giovanni Scambia, Amy L Weaver, Michaela McGree, Lorena Quagliozzi, Carrie Langstraat, Amanika Kumar, William Cliby

Open access · bronzeAbstract read
In one paragraph

Article in International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Surgery in ovarian cancer patients older than 70 years of age and frailty assessment.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Deepa Maheswari NarasimhuluDepartment of Obstetrics and Gynecology, Division of Gynecologic Surgery, Mayo Clinic, Rochester, Minnesota, USA.
Anna FagottiDepartment of Gynecological Oncology, Catholic University of the Sacred Heart, Milano, Lombardia, Italy.ORCID http://orcid.org/0000-0001-5579-335X
Giovanni ScambiaDepartment of Gynecological Oncology, Catholic University of the Sacred Heart, Milano, Lombardia, Italy.ORCID http://orcid.org/0000-0003-2758-1063
Amy L WeaverDepartment of Quantitative Health Sciences, Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota, USA.
Michaela McGreeDepartment of Quantitative Health Sciences, Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota, USA.
Lorena QuagliozziDepartment for Women's and Children's Health and Public Health, Gynecologic Oncology Unit, Policlinico Universitario Agostino Gemelli, Roma, Lazio, Italy.
Carrie LangstraatDepartment of Obstetrics and Gynecology, Division of Gynecologic Surgery, Mayo Clinic, Rochester, Minnesota, USA.ORCID http://orcid.org/0000-0001-9361-8392
Amanika KumarDepartment of Obstetrics and Gynecology, Division of Gynecologic Surgery, Mayo Clinic, Rochester, Minnesota, USA.ORCID http://orcid.org/0000-0002-1470-1305
William ClibyDepartment of Obstetrics and Gynecology, Division of Gynecologic Surgery, Mayo Clinic, Rochester, Minnesota, USA Cliby.William@mayo.edu.ORCID http://orcid.org/0000-0002-7565-9884
Mayo Clinic · USMayo Clinic in Florida · USUniversità Cattolica del Sacro Cuore · ITAgostino Gemelli University Polyclinic · IT

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
Mayo Clinic Center for Clinical and Translational Science (CCaTS UL1 Supplement - Dr. Timothy Curry)UL1TR002377 · NCATS · MAYO CLINIC ROCHESTER · PI VESNA D GAROVIC · 2017 to 2026
$78.4M
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI Zhenkun Lou · 2009 to 2026
$37.0M
NCATS NIH HHS UL1 TR002377NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA136393
6 · The paper itself

Abstract

objectiveWe developed an algorithm that identifies patients at high risk of morbidity/mortality after cytoreductive surgery for advanced ovarian cancer. We have previously shown that the Mayo triage algorithm reduces operative mortality internally, followed by validation using an external low complexity national dataset. However, validation in a higher complexity surgical setting is required before widespread acceptance of this approach, and this was the goal of our study.

methodsWe included patients who underwent debulking surgery (including primary or interval debulking surgery) for stage IIIC/IV ovarian cancer between October 2011 and November 2019 (SCORPION trial patients until May 2016 and non-trial patients thereafter) at Fondazione Policlinico A Gemelli, Italy. Using the algorithm, we classified patients as either high-risk or triage-appropriate and compared 30-day grade 3+ complications and 90-day mortality using a χ

resultsA total of 625 patients were included. The mean age was 58.7±11.4 years, 73.6% (n=460) were stage IIIC, and 63.0% (n=394) underwent primary debulking surgery. Surgical complexity was intermediate or high in 82.6% (n=516) of patients (95.7% (n=377) for primary surgery and 60.2% (n=139) for interval surgery), and 20.3% (n=127) were classified as high-risk. When compared with triage-appropriate patients, high-risk patients had (1) a threefold higher rate of 90-day mortality (6.3% vs 2.0%, p=0.02); (2) a higher likelihood of 90-day mortality following a grade 3+ complication (25.9% vs 10.0%, p=0.05); and (3) comparable rates of grade 3+ complications (21.3% vs 16.1%, p=0.17).

conclusionThe evidence-based triage algorithm identifies patients at high risk of morbidity/mortality after cytoreductive surgery. Triage high-risk patients are poor candidates for surgery when complex surgery is required. This algorithm has been validated in heterogeneous settings (internal, national, and international) and degree of surgical complexity. Risk-based decision making should be standard of care when planning surgery for patients with advanced ovarian cancer, whether primary or interval surgery.

Indexed as

Neoadjuvant TherapyOvarian NeoplasmsAgedAlgorithmsCarcinoma, Ovarian EpithelialClinical Trials as TopicCytoreduction Surgical ProceduresFemaleHumansItalyMiddle AgedNeoplasm StagingRetrospective Studiescytoreduction surgical proceduresovarian cancer

Identifiers

PMID36517075
PMCPMC9972179
OpenAlexW4311474313

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.